Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hypersensitivity Reaction

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 290 articles:
HTML format



Single Articles


    July 2021
  1. SAEKI H, Baba N, Ito K, Yokota D, et al
    Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double-blind, vehicle-controlled trial.
    Br J Dermatol. 2021 Jul 21. doi: 10.1111/bjd.20655.
    PubMed     Abstract available


  2. PROCOPIO-AZEVEDO AC, Rabello VBS, Muniz MM, Figueiredo-Carvalho MHG, et al
    Hypersensitivity reactions in sporotrichosis: A retrospective cohort of 325 patients from a reference hospital in Rio de Janeiro, Brazil (2005-2018).
    Br J Dermatol. 2021 Jul 14. doi: 10.1111/bjd.20646.
    PubMed     Abstract available


    June 2021
  3. BRODERICK C, Christian N, Apfelbacher C, Bosma AL, et al
    The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) Glossary: developing a lingua franca to facilitate data harmonisation and cross-cohort analyses.
    Br J Dermatol. 2021 Jun 16. doi: 10.1111/bjd.20587.
    PubMed     Abstract available


  4. SILVERBERG JI
    Association of atopic dermatitis and autoimmune comorbidities: is it real?
    Br J Dermatol. 2021 Jun 14. doi: 10.1111/bjd.20497.
    PubMed    


  5. JOHANSSON EK
    Psychiatric conditions in children with atopic dermatitis.
    Br J Dermatol. 2021 Jun 11. doi: 10.1111/bjd.20394.
    PubMed    


  6. LINDER M
    Using epidemiological methods to quantify the risk of serious infections in children with atopic dermatitis.
    Br J Dermatol. 2021 Jun 11. doi: 10.1111/bjd.20395.
    PubMed    


  7. WELSH E, Cardenas-de la Garza JA, Cuellar-Barboza A, Franco-Marquez R, et al
    SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19.
    Br J Dermatol. 2021;184:1194-1195.
    PubMed    


    May 2021
  8. TAIEB A, Katoh N
    Regional differences between Japan and the Netherlands in atopic dermatitis patient-reported outcome measures: which interpretation?
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20424.
    PubMed    


  9. VESTERGAARD C
    How clinical phenotypes can translate into taxonomy: can we judge atopic dermatitis by its cover?
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20434.
    PubMed    


  10. JURADO-ESCOBAR R, Dona I, Perkins JR, Laguna JJ, et al
    Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021 May 6. doi: 10.1111/bjd.20440.
    PubMed     Abstract available


  11. NGUYEN C, Yale K, Casale F, Ghigi A, et al
    SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study.
    Br J Dermatol. 2021 May 6. doi: 10.1111/bjd.20435.
    PubMed     Abstract available


  12. SCHNUCH A
    Hand eczema in young people: atopic dermatitis and beyond.
    Br J Dermatol. 2021 May 4. doi: 10.1111/bjd.20142.
    PubMed    


  13. BHANOT A, Peters TJ, Ridd MJ
    Assessing the validity, responsiveness and reliability of the Recap measure of eczema control.
    Br J Dermatol. 2021;184:955-957.
    PubMed    


  14. SIBBALD C
    Long-term safety of dupilumab in children.
    Br J Dermatol. 2021;184:792-793.
    PubMed    


  15. ASCOTT A, Mansfield KE, Schonmann Y, Mulick A, et al
    Atopic eczema and obesity: a population-based study.
    Br J Dermatol. 2021;184:871-879.
    PubMed     Abstract available


    April 2021
  16. BAURECHT H, Welker C, Baumeister SE, Weidnger S, et al
    Relationship between Atopic Dermatitis, Depression and Anxiety: a two-sample Mendelian randomization study.
    Br J Dermatol. 2021 Apr 4. doi: 10.1111/bjd.20092.
    PubMed     Abstract available


    March 2021
  17. SILVERBERG JI, Lai JS, Cella D
    Reliability and meaningful change of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire(R) (PIQ) Item-Banks in adults with atopic dermatitis.
    Br J Dermatol. 2021 Mar 18. doi: 10.1111/bjd.20066.
    PubMed     Abstract available


  18. MIRZA FN, Wang A, Ramachandran SM, Damsky W, et al
    Dupilumab induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo IL-17A expression: a case report.
    Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20064.
    PubMed     Abstract available


  19. DE WIJS LEM, Fujimoto RFT, Andrinopoulou ER, Nijsten TEC, et al
    Dupilumab treatment in atopic dermatitis patients in the Netherlands versus Japan: a comparative cohort study revealing a discrepancy in patient-reported outcome measures.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19897.
    PubMed     Abstract available


  20. MULICK AR, Mansfield KE, Silverwood RJ, Buddu-Aggrey A, et al
    Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort.
    Br J Dermatol. 2021 Mar 2. doi: 10.1111/bjd.19885.
    PubMed     Abstract available


    February 2021
  21. PILKINGTON SM
    The importance of keratinocyte-dendritic cell interactions in understanding fragrance allergy.
    Br J Dermatol. 2021 Feb 18. doi: 10.1111/bjd.19828.
    PubMed    


  22. ABUABARA K, Nicholls SG, Langan SM, Guttman-Yassky E, et al
    Priority research questions in atopic dermatitis: An International Eczema Council eDelphi consensus.
    Br J Dermatol. 2021 Feb 11. doi: 10.1111/bjd.19874.
    PubMed     Abstract available


  23. NAPOLITANO M, Caiazzo G, Fabbrocini G, Balato A, et al
    Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.
    Br J Dermatol. 2021;184:341-343.
    PubMed    


  24. LUCAS JA
    Using electronic health records to examine links between atopic dermatitis and obesity.
    Br J Dermatol. 2021 Feb 1. doi: 10.1111/bjd.19758.
    PubMed    


  25. GONCALO M, Gimenez-Arnau A, Al-Ahmad M, Ben-Shoshan M, et al
    The global burden of chronic urticaria for the patient and society.
    Br J Dermatol. 2021;184:226-236.
    PubMed     Abstract available


    January 2021
  26. ENDRE KMA, Landro L, LeBlanc M, Gjersvik P, et al
    Diagnosing Atopic Dermatitis in Infancy Using Established Diagnostic Criteria: A Cohort Study.
    Br J Dermatol. 2021 Jan 28. doi: 10.1111/bjd.19831.
    PubMed     Abstract available


  27. DROITCOURT C, Vittrup I, Dupuy A, Egeberg A, et al
    The risk of systemic infections requiring hospitalisation in children with atopic dermatitis: a Danish retrospective nationwide cohort study.
    Br J Dermatol. 2021 Jan 21. doi: 10.1111/bjd.19825.
    PubMed     Abstract available


  28. VITTRUP I, Andersen YMF, Droitcourt C, Skov L, et al
    Association between hospital-diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19817.
    PubMed     Abstract available


  29. KAMIDO H, Shimomiya D, Kogame T, Takimoto-Ito R, et al
    Inducible skin-associated lymphoid tissue (iSALT) in a patient with Schnitzler syndrome who manifested wheals on recurrent localized erythema.
    Br J Dermatol. 2021 Jan 14. doi: 10.1111/bjd.19808.
    PubMed     Abstract available



  30. Revolutionizing Atopic Dermatitis, 13-14 December 2020.
    Br J Dermatol. 2021 Jan 11. doi: 10.1111/bjd.19722.
    PubMed    


  31. EXPOSITO-SERRANO V, Curto-Barredo L, Aguilera Peiro P, Gomez Armayones S, et al
    Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
    Br J Dermatol. 2021;184:167-168.
    PubMed    


  32. BOONCHAI W
    What should be in the facial patch testing series for 2020?
    Br J Dermatol. 2021;184:13.
    PubMed    


    December 2020
  33. MORRA DE, Drucker AM
    Tralokinumab for atopic dermatitis: a promising new therapy.
    Br J Dermatol. 2020 Dec 21. doi: 10.1111/bjd.19699.
    PubMed    


  34. MCALEER MA, Jakasa I, Stefanovic N, McLean WHI, et al
    Topical Corticosteroids Normalize both Skin and Systemic Inflammatory Markers in Infant Atopic Dermatitis.
    Br J Dermatol. 2020 Dec 2. doi: 10.1111/bjd.19703.
    PubMed     Abstract available


  35. PAN CX, Jee YH, Moore KJ, Kraft P, et al
    Relationship Between Body Mass Index and Atopic Dermatitis: Critical Appraisal of a Mendelian Randomization Approach in Exploring Causality.
    Br J Dermatol. 2020 Dec 1. doi: 10.1111/bjd.19702.
    PubMed     Abstract available


    November 2020
  36. LICHTER J, Silva E Sousa M, Peter N, Sahli F, et al
    Skin sensitisation to fragrance hydroperoxides: interplay between dendritic cells, keratinocytes and free radicals.
    Br J Dermatol. 2020 Nov 18. doi: 10.1111/bjd.19685.
    PubMed     Abstract available


  37. MIYANO T, Tanaka RJ
    Identification of keratinocyte subpopulations in transcriptome to evaluate drug effects in atopic dermatitis.
    Br J Dermatol. 2020 Nov 8. doi: 10.1111/bjd.19615.
    PubMed    


  38. VAZQUEZ T, Concha JSS, Werth VP
    Patient-oriented outcomes for atopic dermatitis.
    Br J Dermatol. 2020 Nov 8. doi: 10.1111/bjd.19614.
    PubMed    



  39. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS((R)) ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
    Br J Dermatol. 2020;183:e149-e170.
    PubMed     Abstract available


  40. WANG HL, Sun J, Qian ZM, Gong YQ, et al
    Association between Air Pollution and Atopic Dermatitis in Guangzhou, China: Modification by Age and Season.
    Br J Dermatol. 2020 Nov 1. doi: 10.1111/bjd.19645.
    PubMed     Abstract available


  41. SCHUTTELAAR MLA
    The value of ongoing surveillance on the prevalence of contact sensitization.
    Br J Dermatol. 2020;183:800-801.
    PubMed    


  42. BELLON T, Kardaun SH
    CXCL10/IP-10, an early biomarker for late sequelae in DRESS?
    Br J Dermatol. 2020;183:804-805.
    PubMed    


    October 2020
  43. SEARS AV, Woolf RT, Gribaleva E, Abdelrahman W, et al
    Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one-year observational cohort study of the first 100 patients treated.
    Br J Dermatol. 2020 Oct 27. doi: 10.1111/bjd.19631.
    PubMed     Abstract available


  44. IVERT LU, Wahlgren CF, Lindelof B, Dal H, et al
    Association between atopic dermatitis and autoimmune diseases: a population-based case-control study.
    Br J Dermatol. 2020 Oct 22. doi: 10.1111/bjd.19624.
    PubMed     Abstract available


  45. SORIANO LF, Bertram CG, Chowdhury MMU, Cousen P, et al
    Prevalence of allergic contact dermatitis to decyl and lauryl glucoside in the UK and Ireland.
    Br J Dermatol. 2020 Oct 14. doi: 10.1111/bjd.19603.
    PubMed     Abstract available


  46. LAUGHTER MR, Maymone MBC, Mashayekhi S, Arents BWM, et al
    The global burden of atopic dermatitis: lessons from the GBD Study - 1990 to 2017.
    Br J Dermatol. 2020 Oct 2. doi: 10.1111/bjd.19580.
    PubMed     Abstract available


    September 2020
  47. SILVERBERG JI, Toth D, Bieber T, Alexis AF, et al
    Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
    Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19573.
    PubMed     Abstract available


  48. WOLLENBERG A, Blauvelt A, Guttman-Yassky E, Worm M, et al
    Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
    Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19574.
    PubMed     Abstract available


  49. NETTIS E, Fabbrocini G, Ortoncelli M, Pellacani G, et al
    Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients.
    Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19577.
    PubMed     Abstract available


  50. CORK MJ, Thaci D, Eichenfield LF, Arkwright PD, et al
    Dupilumab provides favourable long-term safety and efficacy in children aged >/= 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
    Br J Dermatol. 2020 Sep 24. doi: 10.1111/bjd.19460.
    PubMed     Abstract available


  51. POLAK ME
    Early life regulation of inflammation in atopic dermatitis by microRNA.
    Br J Dermatol. 2020 Sep 20. doi: 10.1111/bjd.19475.
    PubMed    


  52. KORKMAZ P, Boyvat A
    The importance of provided information in contact allergy: key predictors on the road to success in the control of allergic contact dermatitis.
    Br J Dermatol. 2020 Sep 1. doi: 10.1111/bjd.19432.
    PubMed    


  53. PATTINSON R, Bundy C
    Self-management: PROMs can prompt support.
    Br J Dermatol. 2020;183:418-419.
    PubMed    


    August 2020
  54. NAPOLITANO M, Caiazzo G, Fabbrocini G, Balato A, et al
    Increased expression of IL-23A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment.
    Br J Dermatol. 2020 Aug 6. doi: 10.1111/bjd.19464.
    PubMed     Abstract available


  55. SILVERBERG JI, Lei D, Yousaf M, Janmohamed SR, et al
    What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
    Br J Dermatol. 2020 Aug 5. doi: 10.1111/bjd.19457.
    PubMed     Abstract available


  56. RUSSELL E, Walker S, McPherson T
    Diagnosis of Mycoplasma aetiology in Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.
    Br J Dermatol. 2020 Aug 5. doi: 10.1111/bjd.19458.
    PubMed     Abstract available


  57. ARENTS BWM, Leonardi-Bee J
    Eczema and water hardness: another piece of the puzzle found?
    Br J Dermatol. 2020;183:203-204.
    PubMed    


    July 2020
  58. CLAYTON K, Vallejo A, Sirvent S, Davies J, et al
    Machine learning applied to atopic dermatitis transcriptome reveals distinct therapy-dependent modification of the keratinocyte immunophenotype.
    Br J Dermatol. 2020 Jul 30. doi: 10.1111/bjd.19431.
    PubMed     Abstract available


  59. PEREYRA-RODRIGUEZ JJ, Dominguez-Cruz J, Ruiz-Villaverde R, Silvestre JF, et al
    Drug survival of systemic and biologic treatments for moderate-to-severe atopic dermatitis in adults: a multicenter retrospective observational study.
    Br J Dermatol. 2020 Jul 30. doi: 10.1111/bjd.19428.
    PubMed     Abstract available


  60. DRUCKER AM
    Is baricitinib up next for atopic dermatitis?
    Br J Dermatol. 2020 Jul 13. doi: 10.1111/bjd.19226.
    PubMed    


  61. REICH A
    Reliable assessment of atopic dermatitis severity: do we need more tools?
    Br J Dermatol. 2020 Jul 11. doi: 10.1111/bjd.19392.
    PubMed     Abstract available



  62. A study into the drug dupilumab in Japanese adults with moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2020;183:e4-e30.
    PubMed     Abstract available


    June 2020
  63. DE BRUIN-WELLER M
    Systemic treatment in atopic dermatitis after 2018: from experienced-based treatment to evidence-based treatment?
    Br J Dermatol. 2020 Jun 21. doi: 10.1111/bjd.19227.
    PubMed    


  64. OOSTERHAVEN JAF
    How to measure itch in atopic dermatitis?
    Br J Dermatol. 2020 Jun 15. doi: 10.1111/bjd.19225.
    PubMed    


  65. NOUSBECK J, McAleer MA, Hurault G, Kenny E, et al
    miRNA analysis of Childhood Atopic Dermatitis reveals a role for miR-451a.
    Br J Dermatol. 2020 Jun 1. doi: 10.1111/bjd.19254.
    PubMed     Abstract available


  66. WOLLENBERG A, Beck LA, Blauvelt A, Simpson EL, et al
    Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2020;182:e186-e209.
    PubMed     Abstract available


    May 2020
  67. WALBURN J, Sarkany RPE
    Quality of life in the photodermatoses: the hidden toll of photosensitivity.
    Br J Dermatol. 2020;182:1077.
    PubMed    


  68. ARDELEANU M, Shumel B, Rossi AB, Graham NMH, et al
    Response to R. Waldman et al.: 'Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?'
    Br J Dermatol. 2020;182:1310-1312.
    PubMed    


    April 2020
  69. AHOUACH B, Harant S, Ullmer A, Martres P, et al
    Cutaneous lesions in a patient with COVID-19: are they related?
    Br J Dermatol. 2020 Apr 30. doi: 10.1111/bjd.19168.
    PubMed     Abstract available


  70. MAHIL SK, Yiu ZZN, Mason KJ, Dand N, et al
    Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
    Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161.
    PubMed     Abstract available


  71. SILVERBERG JI, Lei D, Yousaf M, Janmohamed SR, et al
    Measurement properties of the Rajka-Langeland severity score in children and adults with atopic dermatitis.
    Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19159.
    PubMed     Abstract available


  72. VON KOBYLETZKI LB
    Partner bereavement can increase the incidence of atopic dermatitis but has no effect on psoriasis.
    Br J Dermatol. 2020 Apr 22. doi: 10.1111/bjd.19046.
    PubMed    


  73. JACHIET M, Bieuvelet S, Argoud AL, Vallee M, et al
    Sleep disturbance in atopic dermatitis: a case-control study using actigraphy and smartphone-collected questionnaires.
    Br J Dermatol. 2020 Apr 22. doi: 10.1111/bjd.19058.
    PubMed     Abstract available


  74. ZOMORODI N, Butt M, Maczuga S, Marks J, et al
    Cost and Diagnostic Characteristics of Toxicodendron Dermatitis in the United States: A retrospective cross-sectional analysis.
    Br J Dermatol. 2020 Apr 15. doi: 10.1111/bjd.19130.
    PubMed     Abstract available


  75. DIZDAREVIC A, Troensegaard W, Uldahl A, Bergendorff O, et al
    Intervention Study to Evaluate the Importance of Information Given to Patients with Contact Allergy. A randomized, investigator-blinded clinical trial.
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19119.
    PubMed     Abstract available


  76. ROLLS S, Owen E, Bertram CG, Bourke JF, et al
    What's in? What's out? Updating the British Society for Cutaneous Allergy Facial Series.
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19127.
    PubMed     Abstract available


  77. BASU P, Tong Y, Hinds BR, Schneider JA, et al
    Nivolumab-induced toxic epidermal necrolysis with retiform purpura.
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19031.
    PubMed    


  78. ELEFTHERIADOU V, Roche L, Bourke JF, Buckley DA, et al
    Allergic contact dermatitis to non-methacrylate nail allergens in the UK.
    Br J Dermatol. 2020 Apr 10. doi: 10.1111/bjd.19116.
    PubMed     Abstract available



  79. Revolutionizing Atopic Dermatitis, 5 April 2020.
    Br J Dermatol. 2020 Apr 3. doi: 10.1111/bjd.19043.
    PubMed    


  80. UTER W
    Patient recall may be of limited use in establishing the clinical relevance of positive patch test reactions (to fragrances).
    Br J Dermatol. 2020;182:831-832.
    PubMed    


  81. WALKER SL
    New therapeutics for leprosy.
    Br J Dermatol. 2020;182:837-838.
    PubMed    


    March 2020
  82. STAUGHTON RCD, Bridgett CK, Noren P, Goulding JMR, et al
    Habitual scratching amplifies and perpetuates atopic dermatitis.
    Br J Dermatol. 2020 Mar 28. doi: 10.1111/bjd.19049.
    PubMed     Abstract available


  83. PARK YM, Seo SJ
    Evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of atopic dermatitis is currently lacking.
    Br J Dermatol. 2020 Mar 5. doi: 10.1111/bjd.18895.
    PubMed    


  84. HARADA K, Irisawa R, Ito T, Uchiyama M, et al
    The effectiveness of dupilumab in alopecia areata patients with atopic dermatitis: a case series of seven patients.
    Br J Dermatol. 2020 Mar 2. doi: 10.1111/bjd.18976.
    PubMed     Abstract available


    February 2020
  85. UTER W, Gefeller O, Mahler V, Geier J, et al
    Trends and current spectrum of contact allergy in Central Europe: Results of the Information Network of Departments of Dermatology (IVDK), 2007 - 2018.
    Br J Dermatol. 2020 Feb 27. doi: 10.1111/bjd.18946.
    PubMed     Abstract available


  86. SILVERBERG JI, Lai JS, Patel K, Singam V, et al
    Measurement properties of the PROMIS Itch Questionnaire - itch severity assessments in adults with atopic dermatitis.
    Br J Dermatol. 2020 Feb 27. doi: 10.1111/bjd.18978.
    PubMed     Abstract available


  87. HALLING AS, Bager P, Skov L, Zachariae C, et al
    The interaction between filaggrin mutations and hard domestic water on the risk of early-onset atopic dermatitis.
    Br J Dermatol. 2020 Feb 21. doi: 10.1111/bjd.18965.
    PubMed     Abstract available


  88. CHAMBRELAN E, Barbarot S, Bekel L, Poizeau F, et al
    Drug survival and post-drug survival of systemic treatments in a national French cohort of children with atopic dermatitis.
    Br J Dermatol. 2020 Feb 9. doi: 10.1111/bjd.18941.
    PubMed     Abstract available


  89. PRICE KN, Krase JM, Loh TY, Hsiao JL, et al
    Racial and Ethnic Disparities in Global Atopic Dermatitis Clinical Trials.
    Br J Dermatol. 2020 Feb 7. doi: 10.1111/bjd.18938.
    PubMed     Abstract available


  90. LEI D, Yousaf M, Janmohamed SR, Vakharia PP, et al
    Validation of Patient-Reported Outcomes Information System Sleep Disturbance and Sleep-Related Impairment in Adults With Atopic Dermatitis.
    Br J Dermatol. 2020 Feb 4. doi: 10.1111/bjd.18920.
    PubMed     Abstract available


  91. CHENG BT, Silverberg JI
    Long-term and multiple hospital readmissions after discharge for Stevens-Johnson Syndrome and toxic epidermal necrolysis.
    Br J Dermatol. 2020 Feb 4. doi: 10.1111/bjd.18923.
    PubMed     Abstract available


  92. DELEURAN M, Vestergaard C
    Real-world evidence vs. randomized control trials.
    Br J Dermatol. 2020;182:275-276.
    PubMed    


    January 2020
  93. SIMPSON EL, Lacour JP, Spelman L, Galimberti R, et al
    Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Topical Corticosteroids: Results from Two Randomised Monotherapy Phase 3 Trials.
    Br J Dermatol. 2020 Jan 29. doi: 10.1111/bjd.18898.
    PubMed     Abstract available


  94. FUXENCH ZCC
    Pain in atopic dermatitis: it's time we addressed this symptom further.
    Br J Dermatol. 2020 Jan 20. doi: 10.1111/bjd.18785.
    PubMed    


  95. WALDMAN RA, DeWane ME, Sloan SB
    Does interleukin-4 inhibition play a role in dupilumab-associated conjunctivitis?
    Br J Dermatol. 2020;182:251.
    PubMed    


    December 2019
  96. MEGNA M, Fabbrocini G
    Psoriasis and atopic dermatitis: different entities with unsolved challenges.
    Br J Dermatol. 2019 Dec 29. doi: 10.1111/bjd.18789.
    PubMed    


  97. LEE HY, Creamer D
    Stevens-Johnson syndrome/toxic epidermal necrolysis: a chronic condition?
    Br J Dermatol. 2019 Dec 18. doi: 10.1111/bjd.18726.
    PubMed    


  98. HENDRICKS AJ, Eichenfield LF, Shi VY
    The Impact of Airborne Pollution on Atopic Dermatitis-A Literature Review.
    Br J Dermatol. 2019 Dec 3. doi: 10.1111/bjd.18781.
    PubMed     Abstract available


  99. BLAKEWAY H, Van-de-Velde V, Allen VB, Kravvas G, et al
    What is the evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of atopic dermatitis? - A systematic review.
    Br J Dermatol. 2019 Dec 3. doi: 10.1111/bjd.18778.
    PubMed     Abstract available


  100. HALLING-OVERGAARD AS, Thyssen JP
    Modifiable risk factors in paediatric atopic dermatitis: is the sun finally shining?
    Br J Dermatol. 2019 Dec 2. doi: 10.1111/bjd.18690.
    PubMed    


  101. O'REILLY P, Kennedy C, Meskell P, Coffey A, et al
    The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: A critically appraised topic.
    Br J Dermatol. 2019 Dec 2. doi: 10.1111/bjd.18746.
    PubMed     Abstract available


    November 2019
  102. WONG AYS, Froslev T, Forbes HJ, Kjaersgaard A, et al
    Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the United Kingdom and Denmark.
    Br J Dermatol. 2019 Nov 28. doi: 10.1111/bjd.18740.
    PubMed     Abstract available


  103. ISMAIL N, Bray N
    Atopic dermatitis: economic burden and strategies for high-quality care.
    Br J Dermatol. 2019 Nov 27. doi: 10.1111/bjd.18636.
    PubMed    


  104. SIBBALD C
    Dupilumab in adolescent atopic dermatitis: interpreting the data.
    Br J Dermatol. 2019 Nov 25. doi: 10.1111/bjd.18627.
    PubMed    


  105. DE WIJS LEM, Nguyen NT, Kunkeler ACM, Nijsten T, et al
    Clinical and histopathological characterization of paradoxical head and neck erythema in atopic dermatitis patients treated with dupilumab: a case series.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18730.
    PubMed     Abstract available


  106. WALSH S, Creamer D
    Shaping specialist treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Br J Dermatol. 2019 Nov 19. doi: 10.1111/bjd.18612.
    PubMed    


  107. RENCZ F
    Cross-country generalizability of quality-of-life scores in atopic dermatitis.
    Br J Dermatol. 2019 Nov 8. doi: 10.1111/bjd.18601.
    PubMed    


  108. ALEXANDER H, Paller AS, Traidl-Hoffmann C, Beck LA, et al
    The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group.
    Br J Dermatol. 2019 Nov 1. doi: 10.1111/bjd.18643.
    PubMed     Abstract available


    October 2019
  109. SINGH P, Silverberg JI
    Under-screening of depression in United States outpatients with atopic dermatitis and psoriasis.
    Br J Dermatol. 2019 Oct 24. doi: 10.1111/bjd.18629.
    PubMed     Abstract available


  110. EGEBERG A, Griffiths CEM, Williams HC, Andersen YMF, et al
    Clinical characteristics, symptoms, and burden of psoriasis and atopic dermatitis in adults.
    Br J Dermatol. 2019 Oct 20. doi: 10.1111/bjd.18622.
    PubMed     Abstract available


  111. CORK MJ, Thaci D, Eichenfield LF, Arkwright PD, et al
    Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Br J Dermatol. 2019 Oct 8. doi: 10.1111/bjd.18476.
    PubMed     Abstract available


    September 2019
  112. STROWD LC, Feldman SR
    Overcoming poor adherence is a major hurdle to managing atopic dermatitis.
    Br J Dermatol. 2019 Sep 30. doi: 10.1111/bjd.18455.
    PubMed    


  113. KATOH N, Kataoka Y, Saeki H, Hide M, et al
    Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.
    Br J Dermatol. 2019 Sep 28. doi: 10.1111/bjd.18565.
    PubMed     Abstract available


  114. THYSSEN JP, Halling-Sonderby AS, Wu JJ, Egeberg A, et al
    Pain severity and use of analgesic medication in adults with atopic dermatitis: a cross-sectional study.
    Br J Dermatol. 2019 Sep 25. doi: 10.1111/bjd.18557.
    PubMed     Abstract available


  115. SILVERBERG JI
    Atopic dermatitis epidemiology: moving beyond cross-sectional studies.
    Br J Dermatol. 2019 Sep 8. doi: 10.1111/bjd.18440.
    PubMed    


    August 2019
  116. ANDERSEN L, Nyeland ME, Nyberg F
    Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the US.
    Br J Dermatol. 2019 Aug 22. doi: 10.1111/bjd.18451.
    PubMed     Abstract available


  117. OLSSON M, Bajpai R, Wee LWY, Yew YW, et al
    The cost of childhood atopic dermatitis in a multi-ethnic Asian population: a cost-of-illness study.
    Br J Dermatol. 2019 Aug 17. doi: 10.1111/bjd.18442.
    PubMed     Abstract available


  118. WOLLENBERG A, Beck LA, Blauvelt A, Simpson EL, et al
    Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Br J Dermatol. 2019 Aug 13. doi: 10.1111/bjd.18434.
    PubMed     Abstract available


  119. GOUIN O, Misery L
    Thymic stromal lymphopoietin, protease-activated receptor 2 and interleukin 1 are involved in the relationship between skin irritation and atopic dermatitis.
    Br J Dermatol. 2019 Aug 9. doi: 10.1111/bjd.18315.
    PubMed    


  120. GONCALO M
    Nail acrylate allergy: the beauty, the beast and beyond.
    Br J Dermatol. 2019 Aug 9. doi: 10.1111/bjd.18313.
    PubMed    


  121. CHABY G, Maldini C, Haddad C, Lebrun-Vignes B, et al
    Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-2016: a four-source capture-recapture estimate.
    Br J Dermatol. 2019 Aug 9. doi: 10.1111/bjd.18424.
    PubMed     Abstract available


  122. LEBWOHL M
    A new era in the treatment of atopic dermatitis.
    Br J Dermatol. 2019 Aug 7. doi: 10.1111/bjd.18349.
    PubMed    


  123. CLAUSEN ML, Agner T
    The inhabitants of our skin.
    Br J Dermatol. 2019 Aug 6. doi: 10.1111/bjd.18312.
    PubMed    


  124. FELMINGHAM C, Yip L, Tam M, Nixon RL, et al
    Allergy to sunscreen and leave-on facial products is not a likely causative mechanism in frontal fibrosing alopecia - perspective from contact allergy experts.
    Br J Dermatol. 2019 Aug 1. doi: 10.1111/bjd.18380.
    PubMed     Abstract available


    July 2019
  125. SZEGEDI A
    Connections between atopic dermatitis and ageing.
    Br J Dermatol. 2019 Jul 30. doi: 10.1111/bjd.18306.
    PubMed    


  126. NICHOLAS MN, Drucker AM
    Depression and anxiety in atopic dermatitis: increasing recognition and opportunities to intervene.
    Br J Dermatol. 2019 Jul 25. doi: 10.1111/bjd.18252.
    PubMed    


  127. ANDERSEN YMF, Egeberg A
    Comparing apples, oranges and atopic dermatitis.
    Br J Dermatol. 2019 Jul 25. doi: 10.1111/bjd.18303.
    PubMed    


  128. NAKASHIMA C, Ishida Y, Kaku Y, Epstein EH Jr, et al
    Dupilumab improved atypical fibrotic skin plaques in atopic dermatitis.
    Br J Dermatol. 2019 Jul 19. doi: 10.1111/bjd.18359.
    PubMed     Abstract available


  129. BETTUZZI T, Penso L, de Prost N, Hemery F, et al
    Trends in mortality rates for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): experience of a single center in France between 1997 and 2017.
    Br J Dermatol. 2019 Jul 19. doi: 10.1111/bjd.18360.
    PubMed     Abstract available


  130. MANOLACHE L, Finlay AY
    Why use an allergy-based quality of life measure in childhood atopic eczema?
    Br J Dermatol. 2019 Jul 17. doi: 10.1111/bjd.18157.
    PubMed    


  131. ANDERSEN L, Nyeland ME, Nyberg F
    Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the UK and the US.
    Br J Dermatol. 2019 Jul 1. doi: 10.1111/bjd.18296.
    PubMed     Abstract available


  132. DE BRUIN-WELLER M
    Time to get rid of the Investigator's Global Assessment as the primary outcome for clinical trials in atopic dermatitis?
    Br J Dermatol. 2019;181:12-13.
    PubMed    


  133. LEE HY
    How different is Stevens-Johnson syndrome/toxic epidermal necrolysis in children?
    Br J Dermatol. 2019;181:10-11.
    PubMed    


  134. DODIUK-GAD RP
    International and multidisciplinary scientific collaborations and networks are advancing knowledge about Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Br J Dermatol. 2019;181:18-19.
    PubMed    


    June 2019
  135. CHOI JY, Dawe R, Ibbotson S, Fleming C, et al
    Topical treatments in atopic dermatitis: unexpectedly low use of emollients; use of topical corticosteroid is higher in juvenile patients, higher in male vs females, and shows independent associations with asthma and depression.
    Br J Dermatol. 2019 Jun 30. doi: 10.1111/bjd.18265.
    PubMed     Abstract available


  136. SHIBATA Y, Serada S, Fujimoto M, Oishi T, et al
    Myosin heavy chain, a novel allergen for fish allergy in patients with atopic dermatitis.
    Br J Dermatol. 2019 Jun 18. doi: 10.1111/bjd.18226.
    PubMed     Abstract available


  137. MOLLANAZAR NK, Qiu CC, Aldrich JL, Tedaldi E, et al
    Use of Dupilumab in HIV-positive Patients: Report of Four Cases.
    Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18222.
    PubMed     Abstract available


  138. STROWD LC, Feldman SR
    Lead with your gut: research-implicated infant gut staphylococcal strains may predict development of atopic dermatitis.
    Br J Dermatol. 2019;180:1296-1297.
    PubMed    


    May 2019
  139. GABES M, Chamlin SL, Lai JS, Cella D, et al
    Evaluation of responsiveness and estimation of smallest detectable change (SDC) and minimal important change (MIC) scores for the Childhood Atopic Dermatitis Impact Scale.
    Br J Dermatol. 2019 May 31. doi: 10.1111/bjd.18204.
    PubMed     Abstract available


  140. DE WIJS LEM, Bosma AL, Erler NS, Hollestein LM, et al
    Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
    Br J Dermatol. 2019 May 30. doi: 10.1111/bjd.18179.
    PubMed     Abstract available


  141. UCHIDA H, Kamata M, Mizukawa I, Watanabe A, et al
    Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: A single-centre retrospective study.
    Br J Dermatol. 2019 May 25. doi: 10.1111/bjd.18163.
    PubMed     Abstract available


  142. JIAO Q, Qian Q, Liu C, Luo Y, et al
    TH 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of ICOS.
    Br J Dermatol. 2019 May 15. doi: 10.1111/bjd.18040.
    PubMed     Abstract available


  143. LEE HH, Patel KR, Singam V, Rastogi S, et al
    Associations of cutaneous and extra-cutaneous infections with Hidradenitis Suppurativa in US children and adults.
    Br J Dermatol. 2019 May 2. doi: 10.1111/bjd.18093.
    PubMed     Abstract available


  144. SONG PI, Armstrong CA
    Novel therapeutic approach with PAC-14028 cream, a TRPV1 antagonist, for patients with mild-to-moderate atopic dermatitis.
    Br J Dermatol. 2019;180:971-972.
    PubMed    


  145. APFELBACHER CJ, Ofenloch R
    Good evidence on measurement properties of the Dermatology Life Quality Index, Itchy Quality of Life and 5-dimensions itch scales in atopic eczema, but problems with structural validity remain.
    Br J Dermatol. 2019;180:979-980.
    PubMed    


  146. EGEBERG A
    Chronic urticaria - bad to the bone?
    Br J Dermatol. 2019;180:979.
    PubMed    


    April 2019
  147. ARMARIO-HITA JC, Pereyra-Rodriguez J, Silvestre JF, Ruiz-Villaverde R, et al
    Treatment of moderate-to-severe Atopic dermatitis with dupilumab in real clinical practice. A multicentre, retrospective case series.
    Br J Dermatol. 2019 Apr 25. doi: 10.1111/bjd.18041.
    PubMed     Abstract available


  148. SILVERBERG JI, Margolis DJ, Boguniewicz M, Fonacier L, et al
    Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
    Br J Dermatol. 2019 Apr 10. doi: 10.1111/bjd.18002.
    PubMed     Abstract available


  149. STANDER S
    How acute stress impacts the itch-scratch cycle in atopic dermatitis: a clinical lesson.
    Br J Dermatol. 2019;180:689-690.
    PubMed    


  150. GOLDENBERG A, Jacob SE
    The atopic paradox.
    Br J Dermatol. 2019;180:704-705.
    PubMed    


  151. MARASCA C, Scala E, Di Caprio R, Raimondo A, et al
    Notch dysregulation and hidradenitis suppurativa, psoriasis, atopic dermatitis and lichen planus: let's talk about Numb.
    Br J Dermatol. 2019;180:950-951.
    PubMed    


    March 2019
  152. BISSONNETTE R, Maari C, Forman S, Bhatia N, et al
    The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study.
    Br J Dermatol. 2019 Mar 28. doi: 10.1111/bjd.17932.
    PubMed     Abstract available


  153. MAGHEN P, Unrue EL, Oussedik E, Cline A, et al
    Regardless of How Risks Are Framed, Patients Seem Hesitant to Use Topical Steroids for Atopic Dermatitis.
    Br J Dermatol. 2019 Mar 27. doi: 10.1111/bjd.17929.
    PubMed     Abstract available


  154. WILLIAMSON S, Merritt J, De Benedetto A
    Atopic Dermatitis in the Elderly: A review of clinical and pathophysiology hallmarks.
    Br J Dermatol. 2019 Mar 21. doi: 10.1111/bjd.17896.
    PubMed     Abstract available


  155. WANG CH, Chi MH, Lin JY, Chung WH, et al
    NUDT15 Polymorphism identified in an Azathioprine Hypersensitivity Syndrome Presenting as Erythema Nodosum and Hepatotoxicity.
    Br J Dermatol. 2019 Mar 6. doi: 10.1111/bjd.17859.
    PubMed     Abstract available


  156. SILVERBERG JI, Gelfand JM, Margolis DJ, Boguniewicz M, et al
    Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults.
    Br J Dermatol. 2019 Mar 5. doi: 10.1111/bjd.17683.
    PubMed     Abstract available


  157. MCPHERSON T, Exton LS, Biswas S, Creamer D, et al
    British Association of Dermatologists guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people 2018.
    Br J Dermatol. 2019 Mar 4. doi: 10.1111/bjd.17841.
    PubMed     Abstract available


  158. CASSIUS C, Davis CJ, Bravard P, Carre-Gislard D, et al
    Look-alike and sound-alike drugs: A potential cause of cutaneous adverse reactions to drugs.
    Br J Dermatol. 2019 Mar 3. doi: 10.1111/bjd.17842.
    PubMed     Abstract available


  159. NAKAMURA T, Haider S, Colicino S, Murray CS, et al
    Different definitions of atopic dermatitis: Impact on prevalence estimates and associated risk factors.
    Br J Dermatol. 2019 Mar 1. doi: 10.1111/bjd.17853.
    PubMed     Abstract available


  160. FURUE M
    Useful components in the stratum corneum for assessment of atopic dermatitis.
    Br J Dermatol. 2019;180:457-458.
    PubMed    


  161. SILVERBERG JI
    Atopic dermatitis: it's not just barrier dysfunction.
    Br J Dermatol. 2019;180:447-448.
    PubMed    


  162. VITTRUP I, Thyssen JP
    Atopic dermatitis and educational achievements - what have we learned?
    Br J Dermatol. 2019;180:452-453.
    PubMed    


  163. HIJNEN DJ
    'En route' to precision medicine.
    Br J Dermatol. 2019;180:455-456.
    PubMed    


  164. WEIDINGER S, Apfelbacher C
    A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate-to-severe atopic eczema.
    Br J Dermatol. 2019;180:435-437.
    PubMed    


  165. OLAYIWOLA O, Ronkainen S, Miller D, High W, et al
    Image Gallery: A case of gadolinium-associated plaques requiring confirmation with mass spectrometry.
    Br J Dermatol. 2019;180:e66.
    PubMed    


    February 2019
  166. SILVERBERG JI, Simpson EL, Ardeleanu M, Thaci D, et al
    Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from 2 phase III trials.
    Br J Dermatol. 2019 Feb 21. doi: 10.1111/bjd.17791.
    PubMed     Abstract available


  167. NAPOLITANO M, Megna M, Fabbrocini G, Nistico SP, et al
    Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Br J Dermatol. 2019 Feb 15. doi: 10.1111/bjd.17779.
    PubMed     Abstract available


  168. IRVINE AD, Mina-Osorio P
    Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide.
    Br J Dermatol. 2019 Feb 13. doi: 10.1111/bjd.17766.
    PubMed     Abstract available


  169. TOTTE JEE, Pardo LM, Fieten KB, Vos MC, et al
    The nasal and skin microbiome are associated with disease severity in pediatric atopic dermatitis.
    Br J Dermatol. 2019 Feb 9. doi: 10.1111/bjd.17755.
    PubMed     Abstract available


  170. YOSIPOVITCH G, Reaney M, Mastey V, Eckert L, et al
    Peak Pruritus Numerical Rating Scale: Psychometric Validation and Responder Definition for Assessing Itch in Moderate-To-Severe Atopic Dermatitis.
    Br J Dermatol. 2019 Feb 6. doi: 10.1111/bjd.17744.
    PubMed     Abstract available


  171. BLAUVELT A, Rosmarin D, Bieber T, Simpson EL, et al
    Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomic regions: data from phase 3 clinical trials.
    Br J Dermatol. 2019 Feb 4. doi: 10.1111/bjd.17703.
    PubMed     Abstract available


  172. STORAN ER, Woolf RT, Smith CH, Pink A, et al
    Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab.
    Br J Dermatol. 2019 Feb 4. doi: 10.1111/bjd.17712.
    PubMed     Abstract available


  173. ERFURT-BERGE C
    Influence on contact allergy of immune-mediated skin diseases such as psoriasis.
    Br J Dermatol. 2019;180:256-257.
    PubMed    


  174. HON KL, Ng WGG, Kung JSC, Cheng NS, et al
    Utility of Pediatric Allergic Disease Quality of Life Questionnaire for childhood eczema.
    Br J Dermatol. 2019 Feb 1. doi: 10.1111/bjd.17710.
    PubMed     Abstract available


    January 2019
  175. REHBINDER EM, Winger AJ, Landro L, Asarnoj A, et al
    Dry skin and skin barrier in early infancy.
    Br J Dermatol. 2019 Jan 13. doi: 10.1111/bjd.17626.
    PubMed     Abstract available


  176. TAUBER M, Apoil PA, Richet C, Laurent J, et al
    Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice.
    Br J Dermatol. 2019 Jan 11. doi: 10.1111/bjd.17629.
    PubMed     Abstract available


  177. THOREL D, Delcampe A, Ingen-Housz-Oro S, Hajj C, et al
    Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Br J Dermatol. 2019 Jan 11. doi: 10.1111/bjd.17627.
    PubMed     Abstract available


  178. LEE YW, Won CH, Jung K, Nam HJ, et al
    Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
    Br J Dermatol. 2019 Jan 8. doi: 10.1111/bjd.17455.
    PubMed     Abstract available


  179. CARR DF, Wang CW, Bellon T, Ressel L, et al
    Serum and blister-fluid elevation and decreased epidermal content of HMGB1 protein in drug-induced Stevens Johnson syndrome/toxic epidermal necrolysis.
    Br J Dermatol. 2019 Jan 5. doi: 10.1111/bjd.17610.
    PubMed     Abstract available


  180. GIMENEZ-ARNAU AM
    Omalizumab: living up to PROMises.
    Br J Dermatol. 2019;180:12-13.
    PubMed    


  181. BERARD F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, et al
    Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Br J Dermatol. 2019;180:56-66.
    PubMed     Abstract available


    December 2018
  182. BAKKER DS, Ariens LFM, van Luijk C, van der Schaft J, et al
    Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
    Br J Dermatol. 2018 Dec 30. doi: 10.1111/bjd.17538.
    PubMed     Abstract available


    November 2018
  183. NOWROUZIAN FL, Ljung A, Nilsson S, Hesselmar B, et al
    Neonatal gut colonisation by Staphylococcus aureus strains with certain adhesins and superantigens is negatively associated with subsequent development of atopic eczema.
    Br J Dermatol. 2018 Nov 25. doi: 10.1111/bjd.17451.
    PubMed     Abstract available


  184. LAGRELIUS M, Wahlgren CF, Matura M, Bergstrom A, et al
    Atopic dermatitis at preschool age and contact allergy in adolescence: a population-based cohort study.
    Br J Dermatol. 2018 Nov 22. doi: 10.1111/bjd.17449.
    PubMed     Abstract available


  185. GENDREAU S, Amiot A, Le Baleur Y, Charpy C, et al
    Gastro-intestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis : a retrospective case series.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17428.
    PubMed     Abstract available


  186. CORAZZA M, Toni G, Musmeci D, Scuderi V, et al
    Dermoscopy of patch test reactions. Study of applicability in differential diagnosis between allergic and irritant reactions.
    Br J Dermatol. 2018 Nov 1. doi: 10.1111/bjd.17389.
    PubMed     Abstract available


    October 2018
  187. SMIRNOVA J, von Kobyletzki L, Lindberg M, Svensson A, et al
    Atopic dermatitis, educational attainment and psychological functioning: a national cohort study.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17330.
    PubMed     Abstract available


  188. HEFEZ L, Zaghbib K, Sbidian E, Valeyrie-Allanore L, et al
    Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients.
    Br J Dermatol. 2018 Oct 3. doi: 10.1111/bjd.17267.
    PubMed     Abstract available


  189. LEUNG DYM
    Can antibiotics be harmful in atopic dermatitis?
    Br J Dermatol. 2018;179:807-808.
    PubMed    


  190. DRUCKER AM, Bercovitch L
    Generating new evidence for old medications: the TREAT trial in paediatric atopic dermatitis.
    Br J Dermatol. 2018;179:813-814.
    PubMed    


    September 2018
  191. PATEL K, Singam V, Vakharia PP, Chopra R, et al
    Measurement properties of three assessments of burden used in atopic dermatitis in adults.
    Br J Dermatol. 2018 Sep 23. doi: 10.1111/bjd.17243.
    PubMed     Abstract available


  192. SIMON M
    Effects of environmental skin stressors on filaggrin degradation products: importance for eczema.
    Br J Dermatol. 2018;179:560-561.
    PubMed    


    August 2018
  193. CLASSEN A, Buhl T, Schubert S, Worm M, et al
    The frequency of specific contact allergies is reduced in psoriasis patients.
    Br J Dermatol. 2018 Aug 12. doi: 10.1111/bjd.17080.
    PubMed     Abstract available


  194. CLAUSEN ML, Edslev SM, Norreslet LB, Sorensen JA, et al
    Temporal Variation of Staphylococcus aureus clonal complexes in Atopic Dermatitis - a follow up study.
    Br J Dermatol. 2018 Aug 2. doi: 10.1111/bjd.17033.
    PubMed     Abstract available


  195. THYSSEN JP
    The trade-off: evolutionary benefits of epidermal filaggrin deficiency on cheek skin came at the price of the atopic dermatitis epidemic.
    Br J Dermatol. 2018;179:235-236.
    PubMed    


  196. WALSH S, Creamer D
    Severe cutaneous adverse reactions syndromes and prescribing autonomy.
    Br J Dermatol. 2018;179:242-243.
    PubMed    


    July 2018
  197. HULSHOF L, Hack DP, Hasnoe QCJ, Dontje B, et al
    Stratum corneum analysis provide a minimal invasive tool to study immune response and skin barrier in atopic dermatitis children.
    Br J Dermatol. 2018 Jul 10. doi: 10.1111/bjd.16994.
    PubMed     Abstract available


  198. THYSSEN JP, Egeberg A
    Cardiovascular disease and atopic dermatitis: epidemiological strengths and limitations.
    Br J Dermatol. 2018 Jul 3. doi: 10.1111/bjd.16939.
    PubMed     Abstract available


  199. TSAKOK T, Woolf R, Smith CH, Weidinger S, et al
    Atopic dermatitis: the skin barrier and beyond.
    Br J Dermatol. 2018 Jul 3. doi: 10.1111/bjd.16934.
    PubMed     Abstract available


  200. BRANDWEIN M, Fuks G, Israel A, Nejman D, et al
    Identification of a unique Staphylococcus aureus ribosomal signature in severe atopic dermatitis.
    Br J Dermatol. 2018 Jul 1. doi: 10.1111/bjd.16936.
    PubMed     Abstract available


    June 2018
  201. AHLSTROM MG, Thyssen JP, Menne T, Midander K, et al
    Short contact with nickel causes allergic contact dermatitis: an experimental study.
    Br J Dermatol. 2018 Jun 29. doi: 10.1111/bjd.16935.
    PubMed     Abstract available


  202. MOCHIZUKI H, Lavery MJ, Nattkemper LA, Albornoz C, et al
    Impact of Acute Stress on Itch Sensation and Scratching Behavior in Atopic Dermatitis Patients and Healthy Controls.
    Br J Dermatol. 2018 Jun 26. doi: 10.1111/bjd.16921.
    PubMed     Abstract available


  203. KALAKI E, Mizara A
    The role of parenting experiences, rather than age of onset or presence of the skin condition, in the development of maladaptive schemas in a community sample of patients with atopic dermatitis.
    Br J Dermatol. 2018 Jun 26. doi: 10.1111/bjd.16920.
    PubMed     Abstract available


  204. HURAULT G, Schram ME, Roekevisch E, Spuls PI, et al
    Relationship and probabilistic stratification of EASI and oSCORAD severity scores for atopic dermatitis.
    Br J Dermatol. 2018 Jun 26. doi: 10.1111/bjd.16916.
    PubMed     Abstract available


  205. DRUCKER AM, Flohr C
    Revisiting atopic dermatitis and cardiovascular disease.
    Br J Dermatol. 2018 Jun 19. doi: 10.1111/bjd.16891.
    PubMed     Abstract available


  206. VON KOBYLETZKI LB, Svensson A
    Building the evidence base for current systemic treatments for severe, chronic atopic dermatitis: methotrexate vs. azathioprine.
    Br J Dermatol. 2018;178:1236-1237.
    PubMed    


  207. SEDDON O, Hughes H
    Staphylococcus aureus and atopic dermatitis: a complex relationship.
    Br J Dermatol. 2018;178:1234.
    PubMed    


  208. DRUCKER AM, Flohr C
    Atopic dermatitis and cardiovascular disease: have we seen enough to refute a causal link?
    Br J Dermatol. 2018;178:1235-1236.
    PubMed    


    May 2018
  209. ZHU TH, Zhu TR, Tran KA, Sivamani RK, et al
    Epithelial Barrier Dysfunctions in Atopic Dermatitis: A Skin-Gut-Lung Model Linking Microbiome Alteration and Immune Dysregulation.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16734.
    PubMed     Abstract available


  210. EL KHOURY M, Assier H, Gener G, Paul M, et al
    Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin, and pristinamycin: clinical history and patch testing.
    Br J Dermatol. 2018 May 10. doi: 10.1111/bjd.16738.
    PubMed     Abstract available


  211. HARKINS CP, McAleer MA, Bennett D, McHugh M, et al
    The widespread use of topical antimicrobials enriches for resistance in Staphylococcus aureus isolated from Atopic Dermatitis patients.
    Br J Dermatol. 2018 May 5. doi: 10.1111/bjd.16722.
    PubMed     Abstract available


  212. SCHMITT J
    After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?
    Br J Dermatol. 2018;178:992-993.
    PubMed    


    April 2018
  213. DARRIGADE AS, Legrand A, Andreu N, Jacquemin C, et al
    Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata.
    Br J Dermatol. 2018 Apr 30. doi: 10.1111/bjd.16711.
    PubMed     Abstract available


  214. MCALEER MA, Jakasa I, Raj N, O'Donnell CPF, et al
    Early life regional and temporal variation in filaggrin-derived natural moisturising factor, filaggrin processing enzyme activity, corneocyte phenotypes and plasmin activity: Implications for atopic dermatitis.
    Br J Dermatol. 2018 Apr 25. doi: 10.1111/bjd.16691.
    PubMed     Abstract available


  215. CHALMERS JR, Thomas KS, Apfelbacher C, Williams HC, et al
    Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
    Br J Dermatol. 2018 Apr 19. doi: 10.1111/bjd.16543.
    PubMed     Abstract available


  216. OOSTERHAVEN JAF
    Interpretability in atopic dermatitis: all about the anchor.
    Br J Dermatol. 2018;178:832-833.
    PubMed    


  217. KEZIC S
    Atopic dermatitis: risk estimates for hand eczema.
    Br J Dermatol. 2018;178:827.
    PubMed    


    March 2018
  218. ROLLS S, Rajan S, Shah A, Bourke JF, et al
    (Meth)acrylate allergy: frequently missed?
    Br J Dermatol. 2018 Mar 10. doi: 10.1111/bjd.16402.
    PubMed    


  219. ABUABARA K, Flohr C
    Is new better than tried and tested? Topical atopic dermatitis treatment in context.
    Br J Dermatol. 2018;178:583-584.
    PubMed    


  220. UTER W
    Extended patch-test screening for fragrance contact allergy: findings and challenges.
    Br J Dermatol. 2018;178:592-593.
    PubMed    


  221. BEWLEY A
    Habit reversal therapy quickly and significantly contributes to the management of children with atopic eczema.
    Br J Dermatol. 2018;178:584-585.
    PubMed    


    February 2018
  222. ENGEBRETSEN KA, Kezic S, Jakasa I, Hedengran A, et al
    Effect of atopic skin stressors on natural moisturizing factors and cytokines in healthy adult epidermis.
    Br J Dermatol. 2018 Feb 27. doi: 10.1111/bjd.16487.
    PubMed     Abstract available


  223. NARLA S, Silverberg JI
    Association between childhood atopic dermatitis, cutaneous, extracutaneous and systemic infections.
    Br J Dermatol. 2018 Feb 25. doi: 10.1111/bjd.16482.
    PubMed     Abstract available


  224. RENCZ F
    Impact of dupilumab on health-related quality of life in patients with atopic dermatitis.
    Br J Dermatol. 2018;178:319-320.
    PubMed    


  225. BISSONNETTE R
    JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis.
    Br J Dermatol. 2018;178:321.
    PubMed    


    January 2018
  226. WANG R, Dunlap RR, Darwish MA, Simpson EL, et al
    Initial validation of the Burden of Disease in Atopic Eczema instrument, a quality of life measure for adult atopic dermatitis.
    Br J Dermatol. 2018 Jan 30. doi: 10.1111/bjd.16398.
    PubMed     Abstract available


  227. KONO M, Akiyama M, Inoue Y, Nomura T, et al
    Filaggrin gene mutations may influence the persistence of food allergies in Japanese primary school children.
    Br J Dermatol. 2018 Jan 25. doi: 10.1111/bjd.16375.
    PubMed     Abstract available


  228. CHABY G, Valeyrie-Allanore L, Duong TA, Lebrun-Vignes B, et al
    Severe cutaneous adverse reactions due to inappropriate medication use.
    Br J Dermatol. 2018 Jan 20. doi: 10.1111/bjd.16365.
    PubMed     Abstract available


  229. DIZON MP, Yu AM, Singh RK, Wan J, et al
    Systematic review of atopic dermatitis disease definition in studies using routinely-collected health data.
    Br J Dermatol. 2018 Jan 16. doi: 10.1111/bjd.16340.
    PubMed     Abstract available


  230. DE BRUIN-WELLER M, Graham NMH, Pirozzi G, Shumel B, et al
    Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Reply from authors.
    Br J Dermatol. 2018 Jan 15. doi: 10.1111/bjd.16348.
    PubMed     Abstract available


  231. THYSSEN JP
    Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with demodex and increased IL-17 levels?
    Br J Dermatol. 2018 Jan 15. doi: 10.1111/bjd.16330.
    PubMed     Abstract available


  232. BACHELEZ H
    Pustular psoriasis and related pustular skin diseases.
    Br J Dermatol. 2018 Jan 15. doi: 10.1111/bjd.16232.
    PubMed     Abstract available


  233. THOMSON J, Wernham AGH, Williams HC
    Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.
    Br J Dermatol. 2018 Jan 6. doi: 10.1111/bjd.16317.
    PubMed     Abstract available


    December 2017
  234. DE WIT J, Totte JEE, van Buchem FJM, Pasmans SGMA, et al
    The prevalence of antibody responses against Staphylococcus aureus antigens in patients with atopic dermatitis: a systematic review and meta-analysis.
    Br J Dermatol. 2017 Dec 16. doi: 10.1111/bjd.16251.
    PubMed     Abstract available


  235. GERBENS LAA, Hamann SAS, Brouwer MWD, Roekevisch E, et al
    Methotrexate and azathioprine in severe atopic dermatitis: a 5-year follow up study of a randomised controlled trial.
    Br J Dermatol. 2017 Dec 13. doi: 10.1111/bjd.16240.
    PubMed     Abstract available


  236. THYSSEN JP, Halling-Overgaard AS, Andersen YMF, Gislason G, et al
    The association between cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis.
    Br J Dermatol. 2017 Dec 6. doi: 10.1111/bjd.16215.
    PubMed     Abstract available


  237. AHMED A, Solman L, Williams HC
    Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Br J Dermatol. 2017 Dec 3. doi: 10.1111/bjd.16046.
    PubMed     Abstract available


  238. VAN DER BENT SAS, Maijer KI, Rustemeyer T
    Image Gallery: Hyperkeratotic hypersensitivity reaction to red pigment tattoo.
    Br J Dermatol. 2017;177:e350.
    PubMed    


    November 2017
  239. TOTTE JEE, Pardo LM, Fieten KB, de Wit J, et al
    The IgG response against Staphylococcus aureus is associated with severe atopic dermatitis in children.
    Br J Dermatol. 2017 Nov 30. doi: 10.1111/bjd.16153.
    PubMed     Abstract available


  240. PALLER AS
    Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild-moderate atopic dermatitis.
    Br J Dermatol. 2017 Nov 30. doi: 10.1111/bjd.16047.
    PubMed    


  241. DE BRUIN-WELLER M, Thaci D, Smith CH, Reich K, et al
    Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized ph
    Br J Dermatol. 2017 Nov 28. doi: 10.1111/bjd.16156.
    PubMed     Abstract available


  242. CHENG L, Sun B, Xiong Y, Hu L, et al
    The minor allele HCP5 rs3099844 A, PSORS1C1 rs3131003 G are associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese: a multicentre retrospective case-control clinical study.
    Br J Dermatol. 2017 Nov 28. doi: 10.1111/bjd.16151.
    PubMed     Abstract available


  243. RUFF SMD, Engebretsen KA, Zachariae C, Johansen JD, et al
    The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis.
    Br J Dermatol. 2017 Nov 24. doi: 10.1111/bjd.16147.
    PubMed     Abstract available


  244. NAKAMURA-NISHIMURA Y, Miyagawa F, Miyashita K, Ommori R, et al
    Serum thymus and activation-regulated chemokine (TARC) is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DIHS).
    Br J Dermatol. 2017 Nov 18. doi: 10.1111/bjd.16132.
    PubMed     Abstract available


  245. VASSEUR P, Pohin M, Jegou JF, Favot L, et al
    Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis.
    Br J Dermatol. 2017 Nov 18. doi: 10.1111/bjd.16137.
    PubMed     Abstract available


  246. STOFFEL E, Maier H, Riedl E, Bruggen MC, et al
    Analysis of anti-TNF-induced skin lesions reveals strong Th1 activation with some distinct immunological characteristics.
    Br J Dermatol. 2017 Nov 16. doi: 10.1111/bjd.16126.
    PubMed     Abstract available


  247. DANBY SG
    Staphylococcus aureus in atopic dermatitis: a diverse problem?
    Br J Dermatol. 2017;177:1164.
    PubMed    


  248. DRUCKER AM
    Making sense of measures of clinical signs for atopic dermatitis.
    Br J Dermatol. 2017;177:1158-1159.
    PubMed    


  249. SILVERBERG JI
    Are moisturizers effective in the treatment of atopic dermatitis?
    Br J Dermatol. 2017;177:1154.
    PubMed    


  250. MELLERIO JE
    Neonatal aggressive systemic mastocytosis.
    Br J Dermatol. 2017;177:1167-1168.
    PubMed    


    October 2017
  251. VAKHARIA PP, Chopra R, Sacotte R, Patel N, et al
    Severity strata for five patient-reported outcomes in adults with atopic dermatitis.
    Br J Dermatol. 2017 Oct 19. doi: 10.1111/bjd.16078.
    PubMed     Abstract available


  252. EGEBERG A
    Cardiometabolic disease in atopic dermatitis: the heart of the matter.
    Br J Dermatol. 2017;177:898-899.
    PubMed    


  253. SEMINARA NM, Pomeranz MK
    Unravelling the links between malignancy, cytokines and neutrophilic eruptions.
    Br J Dermatol. 2017;177:905-906.
    PubMed    


  254. ASERO R
    Towards a better categorization of patients with chronic urticaria.
    Br J Dermatol. 2017;177:903-904.
    PubMed    


    September 2017
  255. NAKAGAWA H, Nemoto O, Igarashi A, Nagata T, et al
    Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase 2, multi-centre, randomised, vehicle-controlled clinical study.
    Br J Dermatol. 2017 Sep 28. doi: 10.1111/bjd.16014.
    PubMed     Abstract available


  256. NOREN P, Hagstromer L, Alimohammadi M, Melin L, et al
    The positive effects of habit reversal treatment of scratching in children with atopic dermatitis: A randomised controlled study.
    Br J Dermatol. 2017 Sep 23. doi: 10.1111/bjd.16009.
    PubMed     Abstract available


  257. MAGLIE R, Di Cesare A, Lazzeri L, Pescitelli L, et al
    Lichen Planus triggered by infliximab biosimilar CT-P13 and recurred during secukinumab treatment.
    Br J Dermatol. 2017 Sep 22. doi: 10.1111/bjd.16003.
    PubMed     Abstract available


  258. SIGURGEIRSSON B, Luger T
    A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response.
    Br J Dermatol. 2017 Sep 21. doi: 10.1111/bjd.15849.
    PubMed    


  259. SHALOM G, Magen E, Babaev M, Horev A, et al
    Chronic Urticaria and Irritable Bowel Syndrome: a Cross-Sectional Study of 11,271 Patients.
    Br J Dermatol. 2017 Sep 14. doi: 10.1111/bjd.15997.
    PubMed     Abstract available


    June 2017
  260. AGNER T
    Biomarkers in contact dermatitis.
    Br J Dermatol. 2017;176:1434-1435.
    PubMed    


    April 2017
  261. SPULS PI, Gerbens LAA, Simpson E, Apfelbacher CJ, et al
    Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.
    Br J Dermatol. 2017;176:979-984.
    PubMed     Abstract available


  262. NANKERVIS H, Thomas KS, Delamere FM, Barbarot S, et al
    What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials.
    Br J Dermatol. 2017;176:910-927.
    PubMed     Abstract available


  263. KHANDPUR S, Porter RM, Boulton SJ, Anstey A, et al
    Drug-induced photosensitivity: new insights into pathomechanisms and clinical variation through basic and applied science.
    Br J Dermatol. 2017;176:902-909.
    PubMed     Abstract available


  264. BROWN SJ
    Evidence-based medicine for atopic eczema: identifying the knowns and unknowns.
    Br J Dermatol. 2017;176:842-844.
    PubMed    


    March 2017
  265. HUANG A, Fiadorchanka N, Brar K, Balderacchi JL, et al
    In-Utero Presentation of Aggressive Systemic Mastocytosis in a Neonate.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15506.
    PubMed     Abstract available


  266. TEO Y, Walsh S, Creamer D
    Cutaneous Adverse Drug Reactions Referrals to a Liaison Dermatology Service.
    Br J Dermatol. 2017 Mar 16. doi: 10.1111/bjd.15461.
    PubMed     Abstract available


  267. ADLER NR, Aung AK, Ergen EN, Trubiano J, et al
    Recent advances in the understanding of severe cutaneous adverse reactions.
    Br J Dermatol. 2017 Mar 3. doi: 10.1111/bjd.15423.
    PubMed     Abstract available


    February 2017
  268. SU JC, Dailey R, Zallmann M, Leins E, et al
    Determining Effects of Superfine Sheep wool in INfantile Eczema (DESSINE): a randomized paediatric cross over study.
    Br J Dermatol. 2017 Feb 9. doi: 10.1111/bjd.15376.
    PubMed     Abstract available


  269. TAN CW, Pang Y, Sim B, Thirumoorthy T, et al
    The association between drugs and bullous pemphigoid.
    Br J Dermatol. 2017;176:549-551.
    PubMed    


  270. STROM MA, Silverberg JI
    Association between atopic dermatitis and extracutaneous infections in US adults.
    Br J Dermatol. 2017;176:495-497.
    PubMed    


  271. THANDAR Y, Gray A, Botha J, Mosam A, et al
    Topical herbal medicines for atopic eczema: a systematic review of randomized controlled trials.
    Br J Dermatol. 2017;176:330-343.
    PubMed     Abstract available


  272. YE YM, Hur GY, Kim SH, Ban GY, et al
    Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome.
    Br J Dermatol. 2017;176:378-386.
    PubMed     Abstract available


  273. VACCARO M, Santarpia M, Calapai G, Mannucci C, et al
    Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
    Br J Dermatol. 2017;176:507-509.
    PubMed    


  274. LEE HY, Walsh SA, Creamer D
    Long term complications of Stevens-Johnson syndrome / Toxic epidermal necrolysis: The spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multi-disciplinary follow up.
    Br J Dermatol. 2017 Feb 1. doi: 10.1111/bjd.15360.
    PubMed     Abstract available


    January 2017
  275. BISHNOI A, Parsad D, Vinay K, Kumaran MS, et al
    Phototherapy using narrowband ultraviolet B and psoralen plus ultraviolet A is beneficial in steroid-dependent antihistamine-refractory chronic urticaria: a randomized, prospective observer-blinded comparative study.
    Br J Dermatol. 2017;176:62-70.
    PubMed     Abstract available


  276. FLYNN A, Molony P, Keeting C, Cullen J, et al
    Image Gallery: Systemic sarcoidosis presenting within the black pigment of a cosmetic tattoo.
    Br J Dermatol. 2017;176:e2.
    PubMed    


  277. GORCZYZA M, Schoepke N, Krause K, Hawro T, et al
    Patients with chronic cold urticaria may benefit from doxycycline therapy.
    Br J Dermatol. 2017;176:259-261.
    PubMed    


  278. VOLKER-TOUW CM, de Koning HD, Giltay JC, de Kovel CG, et al
    Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype.
    Br J Dermatol. 2017;176:244-248.
    PubMed    


  279. THOMSEN SF
    Effectiveness of phototherapy in chronic urticaria.
    Br J Dermatol. 2017;176:8.
    PubMed    


    December 2016
  280. HERMS F, Franck N, Kramkimel N, Fichel F, et al
    Neutrophilic eccrine hidradenitis in 2 patients treated with BRAF inhibitors: a new cutaneous adverse event.
    Br J Dermatol. 2016 Dec 22. doi: 10.1111/bjd.15259.
    PubMed     Abstract available


  281. HELANDER A, Bradley M, Hasselblad A, Norlen L, et al
    Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45.
    Br J Dermatol. 2016 Dec 14. doi: 10.1111/bjd.15174.
    PubMed     Abstract available


    November 2016
  282. BERENTS TL, Lodrup Carlsen KC, Mowinckel P, Skjerven HO, et al
    Transepidermal water loss in infancy associated with atopic eczema at 2 years: a population-based cohort study.
    Br J Dermatol. 2016 Nov 3. doi: 10.1111/bjd.15157.
    PubMed     Abstract available


  283. TOMIDA E, Kato Y, Ozawa H, Hasegawa H, et al
    Causative drug detection by drug-induced lymphocyte stimulation test in drug-induced linear IgA bullous dermatosis.
    Br J Dermatol. 2016;175:1106-1108.
    PubMed    


    October 2016
  284. NOWROUZIAN FL, Lina G, Hodille E, Lindberg E, et al
    Superantigens and adhesins of infant gut commensal Staphylococcus aureus strains and association with subsequent development of atopic eczema.
    Br J Dermatol. 2016 Oct 19. doi: 10.1111/bjd.15138.
    PubMed     Abstract available


  285. LARESE FILON F, Plazzotta S, Rui F, Mauro M, et al
    Ten years incidence of contact dermatitis in a prospective cohort of health care workers in Trieste Hospitals (North East of Italy) 2004-2013.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15118.
    PubMed     Abstract available


    August 2016
  286. PAPO M, Valeyrie-Allanore L, Razazi K, Carteaux G, et al
    Renal replacement therapy during Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients.
    Br J Dermatol. 2016 Aug 11. doi: 10.1111/bjd.14934.
    PubMed     Abstract available


  287. WALSH S, Lew T, Lee HY
    Psychological sequelae of toxic epidermal necrolysis: further insights.
    Br J Dermatol. 2016;175:241.
    PubMed    


    July 2016
  288. CHONG HT, Yang GN, Sidhu S, Ibbetson J, et al
    Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis.
    Br J Dermatol. 2016 Jul 4. doi: 10.1111/bjd.14842.
    PubMed     Abstract available


  289. MOLIN S
    Deciphering the lipidomic profile of irritant contact dermatitis.
    Br J Dermatol. 2016;175:20-1.
    PubMed    


    May 2016
  290. PETRELLI F, Borgonovo K, Cabiddu M, Coinu A, et al
    Antibiotic prophylaxis for skin toxicity induced by anti-EGFR agents: a systematic review and meta-analysis.
    Br J Dermatol. 2016 May 23. doi: 10.1111/bjd.14756.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: